Sugi Predict

Sugi Predict / Compounds / SCHEMBL7991202

SCHEMBL7991202

SCHEMBL7991202

CC(C)(C)OC(=O)N[C@@H](CO[Si](C)(C)C(C)(C)C)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 7/20 0.48
▸ PPARG P37231 6/20 0.46
▸ CTSK P43235 8/20 0.43
▸ CTSS P25774 6/20 0.43
▸ ITGB3 P05106 1/20 0.42
▸ ITGA2B P08514 1/20 0.42
▸ CTSL P07711 1/20 0.42
▸ CTSB P07858 1/20 0.42
▸ ACE P12821 1/20 0.41
▸ PPARD Q03181 2/20 0.41
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ IDO1 P14902 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4388129 1.00 PPARA (0.48) PPARAPPARGCTSKCTSSITGB3
SCHEMBL15129729 1.00 PPARA (0.48) PPARAPPARGCTSKCTSSITGB3
SCHEMBL9691674 0.88 CTSK (0.40) PPARAPPARGCTSKCTSSCTSL
SCHEMBL29376464 0.88 PPARA (0.50) PPARAPPARGCTSKCTSSITGB3
SCHEMBL31757780 0.88 CTSK (0.43) PPARAPPARGCTSKCTSSITGB3
SCHEMBL17688629 0.87 CTSS (0.41) PPARAPPARGCTSKCTSSCTSL
SCHEMBL18104869 0.87 CTSK (0.40) PPARACTSKCTSSCTSLCTSB
SCHEMBL4745237 0.87 CTSK (0.41) PPARACTSKCTSSCTSLCTSB
SCHEMBL3617062 0.87 CTSK (0.41) PPARACTSKCTSSCTSLCTSB
SCHEMBL3617063 0.87 CTSK (0.41) PPARACTSKCTSSCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0792170-A4 RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS NEORX CORP (US) 2000-03-15 — — EP claimed
EP-0792170-A1 RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS NEORX CORPORATION (US) 1997-09-03 — — EP claimed
WO-1995002418-A1 RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS NEORX CORPORATION (US) 1995-01-26 — — WO claimed
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia PTC THERAPEUTICS, INC. (US) 2025-08-12 — — US disclosed
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 — — EP disclosed
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-17 — — US disclosed
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
WO-2025036479-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2025-02-20 — — WO disclosed
CN-118852545-A Polymer carrier, pharmaceutical composition and application thereof 锐康九域(厦门)医药科技有限公司 2024-10-29 — — CN disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 — — CN disclosed
EP-4419525-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2024-08-28 — — EP disclosed
US-20170081327-A1 DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA VITAE PHARMACEUTICALS, LLC 2017-03-23 — — US disclosed
US-9481674-B1 Dihydropyrrolopyridine inhibitors of ROR-gamma VITAE PHARMACEUTICALS, INC. (US) 2016-11-01 — — US disclosed
WO-2016153023-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME 国立研究開発法人国立長寿医療研究センター 2016-09-29 — — WO disclosed
CN-103626825-B The glycogen phosphorylase inhibitors cholic acid derivative of target liver, its preparation method and medicinal use CHENGDE MEDICAL UNIVERSITY (CN) 2015-10-07 — — CN disclosed
US-20080255213-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-10-16 — — US disclosed
CN-1053188-C Quinolizinone type compounds ABBOTT LAB (US) 2000-06-07 — — CN disclosed
US-5783171-A Radionuclide metal N2 S2 chelates substituted with glucose and biotin moieties NEORX CORPORATION (US) 1998-07-21 — — US disclosed
CN-1137273-A Quinolizinone type compounds ABBOTT LAB (US) 1996-12-04 — — CN disclosed
US-5137884-A Antibiotics MERCK & CO., INC. (US) 1992-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255213-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS SRM, SAT1, SMS PPARA 189/4885PPARG 180/4885CTSK 3780/4885
US-20170081327-A1 DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA RORC, RORB, RORA PPARA 57/4885PPARG 21/4885CTSK 4223/4885
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia SF3B5, SF3B2, SF3B1 PPARA 3910/4885PPARG 4033/4885CTSK 4597/4885
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NQO1, VHL, SDHA PPARA 634/4885PPARG 332/4885CTSK 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.